Approval · Notice of Compliance 22594 · 2019
ZERBAXA: Notice of Compliance 22594
Issued August 30, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22594
- Date
- August 30, 2019
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- To obtain market authorization for a nosocomial pneumonia indication
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZERBAXA | Not yet assigned | — |
Medicinal ingredients
- TAZOBACTAM SODIUM 0.5 G per VIAL
- CEFTOLOZANE 1 G per VIAL